Expert Opinion on Drug Safety

Papers
(The H4-Index of Expert Opinion on Drug Safety is 23. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)
ArticleCitations
Adverse event profiles of drug-induced decreased libido: an assessment of the US food and drug administration Adverse Event Reporting System138
Comparison of adverse events of poly adenosine diphosphate ribose polymerase inhibitors in patients with ovarian cancer using the United States Food and Drug Administration Adverse Event Reporting Sys131
Adverse events in patients with cardiovascular disease taking proton pump inhibitors105
Safety concerns associated with various types of statins: a disproportionality analysis of the FAERS database58
The safety of phthalate-containing medications used during pregnancy47
Novel insights into post-marketing AEs associated with bempedoic acid: a comprehensive analysis utilizing the FAERS database42
Safety profile of isocitrate dehydrogenase inhibitors in cancer therapy: a pharmacovigilance study of the FDA Adverse Event Reporting System42
Exploration and evaluation of adverse event signals of droxidopa based on the FAERS database41
Drug-induced hepatitis B virus reactivation: insights from FAERS database analysis38
The role of artificial intelligence in pharmacovigilance for rare diseases36
Safety assessment of brexanolone in the FAERS database: real adverse event analysis and discussion of side effects36
A real-world pharmacovigilance study of QT interval prolongation and Torsades de Pointes associated with CDK4/6 inhibitors in breast cancer patients: findings from the FDA adverse event reporting syst35
Assessment of adverse events of the novel antiepileptic drug lamotrigine: a real-world pharmacovigilance study based on FAERS29
Infectious events in patients with alopecia areata treated with JAK inhibitors: low burden and minimal impact on persistence in treatment29
Mechanism and clinical utility of abatacept in the treatment of rheumatoid arthritis28
Assessment of adverse events related to anti-interleukin-6 receptor monoclonal antibodies using the FDA adverse event reporting system: a real-world pharmacovigilance study28
Exploration of cardiac adverse events associated with relugolix and degarelix: a multi-center pharmacovigilance study based on the FAERS database27
Why is pharmacovigilance essential for biosimilars?27
An update on the cognitive safety of antimuscarinics in the treatment of overactive bladder27
An updated safety review of Hidradenitis Suppurativa treatment options24
Underuse of GLP-1 receptor agonists in the management of type 2 diabetes despite a favorable benefit-safety profile24
Hypogammaglobulinemia and infections in patients with multiple sclerosis treated with anti-CD20 monoclonal antibodies: a systematic review and meta-analysis of observational studies24
Newly identified adverse events of enzalutamide using the food and drug administration adverse event reporting system23
Safety concerns associated with BACE1 inhibitors – past, present, and future23
0.19126009941101